Merck & Co. and Eisai have to deal with the reality that yet another phase 3 trial of their combination of Keytruda and ...

Co., Inc. (NYSE:MRK) and Eisai Co., Ltd. (TYO:4523) have announced the latest outcomes from their Phase 3 LEAP-015 trial, ...

Following the resounding success of the 7th China International Import Expo (CIIE), the CIIE Bureau has embarked on the ...

The quadrivalent HPV vaccine, developed by multinational pharmaceutical company Merck, was approved on Jan 8 for males on the Chinese mainland. The vaccine targets HPV types 6, 11, 16 and 18. The ...

HCA Healthcare on Friday forecast 2025 profit above estimates, expecting elevated demand for medical procedures and lower ...

Yiren Digital Ltd. ("Yiren Digital" or the "Company"), an AI-powered platform providing a comprehensive suite of financial and lifestyle services in China, was recognized for its outstanding ...

Hoth Therapeutics, Inc. (the "Company" or "Hoth Therapeutics"), a biopharmaceutical company, today announced that it has received notification from the Listing Qualifications Department of The Nasdaq ...

Following the resounding success of the 7th China International Import Expo (CIIE), the CIIE Bureau has embarked on the ...

Business leaders in Davos joined calls by U.S. President Donald Trump for the European Union to speed up efforts to reduce ...

Big business has an inside track in the second Trump presidency, and people with a stake in those businesses have reason to ...

J&J JNJ announced fourth-quarter and full-year 2024 results, starting the earnings season for the drug and biotech sector.

Merck and Eisai reported new data for a drug regimen of Keytruda and Lenvima. Elsewhere, AstraZeneca expanded in Canada and ...